Colorectal Cancer Treatment Future Directions
|
|
- Rose McKinney
- 6 years ago
- Views:
Transcription
1 Colorectal Cancer Treatment Future irections Margot F. Sweed CRNP Fox Chase Cancer Center April 2005 What s the Target? Agents in clinical trials PTK 787/ZK SUO11248 Panitumumab Mapatumumab Sorafemib Pharmacogenomics what s the best treatment? Agents Targeting the VEGF Pathway Anti-VEGF antibodies (bevacizumab) Ribozymes (Angiozyme) P P P P VEGFR-1 VEGF P P P P VEGFR-2 Endothelial cell Soluble VEGF receptors (VEGF-Trap) Anti-VEGFR antibodies (IMC-1121b) Small-molecule VEGFR inhibitors (PTK-787) The VEGF Family of Angiogenic Factors VEGFs are a family of angiogenic factors secreted by tumors in response to hypoxia and other stimuli Five members of the VEGF family play important roles in angiogenesis:, VEGF-B,,, VEGF-E VEGFs induce endothelial cell division and migration resulting in the formation of new blood vessels vorak HF, et al. Curr Top Microbiol Immunol. 1999;237: VEGFs Bind and Activate VEGF Receptors on Endothelial Cells Extracellular Intracellular VEGF-B VEGFR-1/Flt-1 VEGF-E VEGFR-2/KR Adapted from vorak HF. J Clin Oncol. 2002;20(21): Tyrosine Kinase VEGFR-3/Flt-4 Lymphangiogenesis Tumor metastasis Signal Transduction Receptor-ligand interactions at the cell- surface trigger messaging pathways within the cell that direct tumor cell survival, proliferation and differentiation. The systems that convey cell surface signals to the cytoplasm and nucleus are mediated through protein-protein communication. signal transduction Cross talk between pathways Cohen SJ, Cohen RB, Meropol NJ,
2 PTK/ZK A multi-vegf Receptor Inhibitor PTK/ZK inhibits activation of VEGF receptors: VEGFR-1, VEGFR-2, and VEGFR-3 Binds and Inhibits A Only Extracellular VEGF-B VEGF-E Complete inhibitor of the VEGF receptor tyrosine kinases that are critical for tumor angiogenesis and metastasis 1,2 PTK/ZK is being codeveloped by Pharma AG and Schering AG, Germany 1. Wood JM, et al. Cancer Res. 2000;60: Bold G, et al. J Med Chem. 2000;43(12): Intracellular VEGFR-1/Flt-1 VEGFR-2/KR VEGFR-3/Flt-4 Adapted from vorak H. J Clin Oncol. 2002;20(21): Hsei V, et al. Pharm Res. 2002;19(11): Lymphangiogenesis Tumor metastasis PTK/ZK Phase III CONFIRM Trials Two multinational, randomized, double-blind, blind, placebo-controlled controlled trials in patients with metastatic colorectal cancer 1,250 mg PTK/ZK administered orally once daily in combination with oxaliplatin in the FOLFOX4 regimen CONFIRM 1: Previously untreated patients Endpoint: Progression-free survival and overall survival CONFIRM 2: Patients who have failed Irinotecan/5 FU Endpoints: Overall survival Previously untreated patients CONFIRM-1 Multinational, randomized, phase III trial R A N O M I Z E PTK/ZK 1,250 mg/day p.o. Placebo 0 Interim safety Final analysis: analysis Progression-free and overall survival Patients who have failed irinotecan/5-fu based therapy CONFIRM-2 Multinational, randomized, phase III trial R A N O M I Z E PTK/ZK 1,250 mg/day p.o. Placebo 0 Interim safety Final analysis: analysis Overall survival PTK/ZK + Oxaliplatin-based Chemotherapy is Generally Well Tolerated in Patients with Metastatic Colorectal Cancer PTK/ZK + FOLFOX4 (N=35) Grade 3 / 4, adverse events >5% N(%) Neutropenia 9 (26) izziness/lightheadedness 6 (17) Fatigue 4 (11) iarrhea 5 (14) Common mild adverse events of the combination include nausea (69%), neuropathy (77%), vomiting (54%) and diarrhea (54%) Steward WP, et al. Presented at the 40th Annual Meeting of ASCO
3 SU11248 is a tyrosine kinase inhibitor that blocks activation of receptor tyrosine kinases (RTKs( RTKs) ) on tumor cells and tumor vasculature. Image not available SU11248 Overview A Selective RTK inhibitor Small molecule Good oral bioavailability Inhibits multiple receptor tyrosine kinases (RTKs) expressed on iverse tumor cells VEGFR, PGFR, KIT, FLT3 Endothelium, pericytes, and stroma VEGFR, PGFR Potential to both directly and indirectly (through antiangiogenesis) inhibit growth of multiple tumor types Sun et al. J Med Chem. 2003;46: Mendel et al. Clin Cancer Res. 2003;9: PGFR = platelet-derived growth factor receptor; VEGFR = vascular endothelial growth factor receptor. Sugen Phase II -SUO11248 in Metastatic CRC that has not responded to previous treatment w/ Irinotecan, Oxaliplatin, and fluoropyrimidine with or w/o Oral SUO11248 days Repeat every 42 days. Side effects- HTN, hand-foot syndrome, dysesthesias, diarrhea, fatigue The EGFR signaling pathway regulates cell differentiation, proliferation, migration, angiogenesis and apoptosis. In cancer cells, this can all be deregulated. EGFR (HER-1) is a transmembrane glycoprotein. The extracellular domain of EGFR is a ligand-binding site for transforming growth factor (TGF) and EGF. Blockade downstream results in : 1. Inhibition of cell growth 2. Promotes apoptosis 3. Inhibits angiogenesis Potentiates chemotherapy/xrt Harari. CCR, 2000; Ciardeiello & Tortora. CCR, Cetuximab shows activity in CRC patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Chung KY, 2005 N=16 pts EGFR negative 4 had PR (greater than 50% reduction in measurable disease) EGFR positivity has little/no predictive value to response Higher EGFR higher response rate Inconsistent / imperfect IHC methodology: Archived/ stored tissue- decline in staining intensity Interobserver variability in definitions of expression Chung KY, et al. (2005) J Clin Oncol vol 23; no 9 pp1-8 EGFR Staining Intensity vs. Response Cunningham et al. NEJM 2004 Is EGFR expression predictive of response? Cetuximab + Irinotecan Cetuximab Alone EGFR Staining Intensity N RR N RR Faint Weak- Moderate Strong 53 21% 21 5% 89 25% 55 13% 75 23% 34 12% 3
4 Skin Reaction-Efficacy Cetuximab +/- Irinotecan Is rash predictive of response? RR% Cetux/I Cetux Surv (mo.) RR% Surv (mo.) none Grade Grade any An Exploratory Pharmacogenomic Study of Cetuximab Monotherapy in Metastatic CRC (IRB ; 002; BMS CA ) Examine protein and mrna profiles in many different genes which are involved in regulation and activation of the EGFR pathway in order to predict response to Erbitux treatment. To evaluate the relationship between grade >2 skin rash and tumor response rates. Feasibility of escalating the weekly dose. Explore whether additional genes can be identified that are predictive of response to Erbitux. Allows EGFR negative patients Cunningham NEJM 2004 Panitumumab (ABX-EGF) Fully human monoclonal antibody that is directed against the epidermal growth factor receptor. Only rare serious allergic reaction reported. In phase II trial. Binds with higher affinity to the EGFR than Cetuximab. Mapatumumab (HGS-ETR1) Agonistic human monoclonal antibody that binds to the TRAIL receptor 1 protein, and induces apoptosis (programmed cell death). TRAIL (tumor necrosis factor apoptosis inducing ligand) receptor -11 is often called the death receptor. This antibody stimulates the TRAIL receptor-1 protein to trigger cell death like native TRAIL but with a longer ½ life and specificity for TRAIL receptor 1. phase II in Germany Human Genome Sciences, 2005 Sorafemib (BAY ) Small molecule (intracellular signaling) targets VEGFR-2, VEGFR-3, PGFR, c-c KIT and Raf kinase. Signaling pathway to inhibit cell proliferation and the signaling cascade to inhibit tumor angiogenesis. Preclinical data show additive activity when sorafenib is combined with chemotherapy. Combination studies in CRC underway. Adjuvant Therapy Phase III (NSABP C-08) C Flourouracil,, Leucovorin, and Oxaliplatin with or without bevacizumab in treating patients undergone surgery for stage II or stage III colon cancer. Phase III (NCCTG-N0147) N0147) Irinotecan and/or Oxaliplatin plus 5-Fluorouracil 5 /Leucovorin with or without Cetuximab after curative resection for patients with colon cancer Cohen SJ, Cohen RB, Meropol NJ,
5 WHAT WORKS Vesell ES: Advances in pharmacogenetics & pharmacogenomics. J Clin Pharmacol 40: ,2000. Evans WE, McLeod HL: Pharmacogenomics-rug disposition, drug targets and side effects. N Engl J Med 348: , Genetic determinants are involved in 20% to 95% of differences in drug pharmacokinetic and pharmacodynamic processes. These determinants are polymorphisms (changes) in genes directing drug transport and metabolism, cellular targets, signaling and response pathways that remain constant throughout the lifetime. Pharmacogenomics Thymidylate Synthase (TS) expression Microsatellite Instability (MSI) Microsatellites are repeating NA sequences. MSI is demonstrated when the length of NA sequences in a tumor differs from that in nontumor tissue. 5 - FU inhibits Thymidylate Synthase (TS) enzyme = decreased NA synthesis 5-FU attacks Increased expression of TS=low chance response to 5 FU based therapy. Polymorphisms (changes) in TS gene may predict for how individuals will respond to 5FU based regimen thymidylate synthase deoxyuriylate thymidylate thymidine triphosphate NA synthesis and repair Thymidylate Synthase etermination By IHC ECOG 4203 High TS Low TS R a n d o m i z e IROX + FOLFOX + FOLFOX + *Tissue block from metastatic site required for all patients Microsatellite Instability (MSI) is a feature of Hereditary Nonpolyposis CRC (HNPCC) MSI is a NA abnormality present in >90% of HNPCC-associated colorectal tumor tissue MSI indicates an increased likelihood of HNPCC MSI is not diagnostic of HNPCC; also seen in 15% of sporadic colorectal cancer tissue MSI analysis requires access to slides of archival paraffin-embedded colorectal tumor specimen Nat Med 1996;2: Myriad Genetic Laboratories HNPCC Results From Failure of Mismatch Repair (MMR) Genes Base pair mismatch T C T A C A G C T G Normal NA repair efective NA repair (MMR+) T C G A C A G C T G Τ C Τ A C A G C T G T C T A C A G A T G 5
6 Mismatch Repair Failure Leads to Microsatellite Instability (MSI) Normal MICROSATELLITE INSTABILITY 10% 15% 15% of sporadic tumors have MSI 95% of HNPCC tumors have MSI Microsatellite instability Addition of repeated NA Electrophoresis gel Normal MSI tumor Surgery ECOG 5202: Stage II Colon Cancer Tumor block risk assessment based on biology (18q/MSI) Accrual Goal: 3,125 High-risk (MSS and 18q Loss) Low-risk (MSI + or no loss 18q) Arm A: Leucovorin 500 mg/m FU mg/m 2 q 1 wk x 6 x 4 cycles Arm B: Leucovorin 500 mg/m 2 IV bolus + 5-FU mg/m 2 IV bolus + Observation Implications for practice CRC cancer is complex. All colon cancers are not genetically identical. Targeted therapy still has side effects. eveloping new agents is important, but we must also learn how best to match those we have with the patients and tumors most likely to benefit. HIT THE TARGET!!! Slide not available 6
ADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationPharmacy Management Drug Policy
11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More information2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?
Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationCHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012
CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationColorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?
Critical Reviews in Oncology/Hematology 55 (2005) 67 81 Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice? Andrea Mancuso, Cora N. Sternberg Department of Medical
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More informationThe Role of Targeted Therapy in Metastatic Colorectal Cancer Patient Care
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/conversations-colorectal-cancer/the-role-of-targeted-therapy-inmetastatic-colorectal-cancer-patient-care/10272/
More informationVascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer
GASTROENTEROLOGY 2010;138:2163 2176 Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder* Heinz Josef Lenz*, *Division
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationNuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?
Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationThe treatment of metastatic colorectal cancer in 2007
The treatment of metastatic colorectal cancer in 2007 Prof Eric Van Cutsem, MD, PhD Gastrointestinal Oncology Unit University Hospital Gasthuisberg Leuven - Belgium CRC is a major health concern Life-time
More informationTargeted and Chemotherapeutic Approaches to Management of Metastatic Colorectal Cancer. Nicole M. Ross, MSN, CRNP, AOCNP Fox Chase Cancer Center
Targeted and Chemotherapeutic Approaches to Management of Metastatic Colorectal Cancer Nicole M. Ross, MSN, CRNP, AOCNP Fox Chase Cancer Center Learning Objectives Critically evaluate current clinical
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationBiologics Effects of Targeted Therapeutics
Report on the isbtc Mini-symposium on Biologics Effects of Targeted Therapeutics Michael B. Atkins, MD Beth Israel Deaconess Medical Center Louis Weiner, M.D. Fox Chase Cancer Center Report on the isbtc
More informationDoctor Discussion Guide
Talking to your healthcare provider about LONSURF (trifluridine and tipiracil) tablets If you have colon or rectal cancer that has spread to other parts of your body and have previously been treated with
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationNew Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL
New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial
More informationAssessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.
Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers. Soheila Hamidpour MD, Madhusudhana S MD. MMR deficient colorectal tumors can be present
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationMolecular Oncology, oncology parameters see each test
Molecular Oncology, oncology parameters see each test DPD deficiency Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is an autosomal recessive metabolic disorder in which there is absent or
More informationTargeting colorectal cancer with human anti-egfr monoclonocal antibodies: focus on panitumumab
REVIEW Targeting colorectal cancer with human anti-egfr monoclonocal antibodies: focus on panitumumab George P Kim Axel Grothey College of Medicine, Mayo Clinic Abstract: The human anti-epidermal growth
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationDrug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
More informationLONSURF (trifluridine-tipiracil) oral tablet
LONSURF (trifluridine-tipiracil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationBy: Tania Cortas, MD Arizona Oncology 03/10/2015
By: Tania Cortas, MD Arizona Oncology 03/10/2015 Epidemiology In the United States, CRC incidence rates have declined about 2 to 3 percent per year over the last 15 years Death rates from CRC have declined
More informationGenetic Modifiers of Chemotherapy for Colorectal Cancer
Genetic Modifiers of Chemotherapy for Colorectal Cancer September 27, 2011 John M. Carethers, M.D. Professor of Internal Medicine University of Michigan 1,233,700 cases/year Worldwide ~146,000 cases/year
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationReview Article Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
BioMed Research International Volume 2016, Article ID 7590245, 14 pages http://dx.doi.org/10.1155/2016/7590245 Review Article Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal
More informationInnovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III. Tarceva TM
Innovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III Tarceva TM Tarceva TM (erlotinib HCl) High-affinity, reversible inhibitor of HER1/EGFR Tyrosine
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014 DISCLAIMER Not a Substitute for Professional Advice This report
More informationOHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer
OHTAC Recommendation KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer Presented to the Ontario Health Technology Advisory Committee in August, 2010 December 2010 Issue Background In February
More informationBevacizumab is currently licensed for the following indication relevant for this NICE review:
Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationAssociation of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients
Colorectal Cancer Association of Canada Learning about Colorectal Cancer A Personalized Treatment Guide for Patients Avastin is a trademark of Genentech, Inc., Used under licence. Camptosar is a registered
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationOffice of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Panitumumab (Vectibix ) RUTHANN M. GIUSTI, KAUSHIKKUMAR A. SHASTRI, MARTIN H. COHEN, PATRICIA KEEGAN, RICHARD PAZDUR Office of Oncology
More informationA thesis submitted in partial fulfillment of the requirements for the degree in Master of Science
Western University Scholarship@Western Electronic Thesis and Dissertation Repository November 2012 The Cost-Effectiveness of Combination Treatment Consisting of Either Cetuximab or Panitumumab plus FOLFIRI
More informationThe Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis
The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis Nam Deuk Kim, Ph.D. Pusan National University Contents Part 1. The process of angiogenesis Part 2. The role of angiopoietins
More informationOpinion 17 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 October 2012 VECTIBIX 20 mg/ml, concentrate for solution for infusion B/1 vial of 5 ml (CIP code: 3400957181857)
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationCurrent Status of Studies on Targeted Therapy for Renal Cell Carcinoma
294 Chin J Clin Oncol (2008) 5: 294~298 DOI 10.1007/s11805-008-0294-x Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma Shaoqi Wang 1 Shaoxiang Wang 2 Juan Wang 1 1 Department of Oncology,
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationAdjuvant Treatment of Colorectal Cancer
Adjuvant Treatment of Colorectal Cancer Adjuvant Treatment of Colorectal Cancer Brian M. Wolpin, MD; Jeffrey A. Meyerhardt, MD, MPH; Harvey J. Mamon, MD, PhD; Robert J. Mayer, MD Dr. Wolpin is Instructor
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationNursing s Role in the Management of New Oral Chemotherapy Agents
Nursing s Role in the Management of New Oral Chemotherapy Agents Mechelle Barrick BSN, RN, OCN, CCRP Clinical Research Nurse Coordinator Greater Baltimore Medical Center mbarrick@gbmc.org THE NURSES ROLE
More informationRelated Policies None
Medical Policy MP 2.04.53 BCBSA Ref. Policy: 2.04.53 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationClinical Policy: Regorafenib (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationMetastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage. Dr Lee-Ann Jones
Metastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage Dr Lee-Ann Jones Aim Metastatic Colorectal Cancer: Past: 5FU, oxaliplatin, irinotecan..blanket treatment
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More information1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?
1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More information